Retatrutide

Retatrutide is a next-generation synthetic peptide that simultaneously activates three distinct receptor systems: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GcgR (glucagon receptor). This unique triple agonism produces a layered metabolic effect that significantly exceeds what single or dual-agonist compounds achieve.

GLP-1R activation suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. GIPR activation further amplifies insulin release and has been linked to reduced fat storage and improved lipid profiles. GcgR activation increases hepatic glucose output, elevates basal metabolic rate, and stimulates thermogenesis in brown adipose tissue — creating an energy-expenditure effect that counteracts the metabolic adaptation seen with caloric restriction alone.

Structurally, Retatrutide incorporates an α-aminoisobutyric acid (Aib) residue at position 2 — a non-natural amino acid modification that confers resistance to DPP-4 enzymatic degradation, enabling the compound's extended ~6-day half-life. A C18 fatty-acid chain conjugated via a γGlu-miniPEG linker at Lys₁₂ provides albumin binding for sustained release, mirroring the design strategy used in established GLP-1 analogues.

Preclinical research has demonstrated reductions in body weight, visceral and subcutaneous adiposity, fasting glucose, and markers of hepatic steatosis — with a cardiovascular and hepatoprotective profile that distinguishes Retatrutide from first-generation GLP-1 agonists.

Buy more vials, pay for fewer. Deals apply automatically per compound in your cart — the more you stock up, the less you pay per vial.